☆ 4.6 Article

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

ESMO OPEN (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay et al.

Summary: Despite the heterogeneity of small cell lung cancer (SCLC), four subtypes have been identified based on tumor expression data, each showing different responses to treatment. SCLC-I subtype benefits the most from immunotherapy, while other subtypes have vulnerabilities to different inhibitors. Matching tumor subtype to therapy and manipulating subtype switching during treatment may enhance response depth and duration for SCLC patients.

CANCER CELL (2021)

添加到收藏夹

Correction Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)

Borghaei

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen Liu et al.

Summary: IMpower133 trial showed that adding atezolizumab to CP/ET for first-line treatment of ES-SCLC significantly improved patients' overall survival. Atezolizumab demonstrated potential efficacy in treating ES-SCLC.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

M.C. Garassino et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype

Taofeek K. Owonikoko et al.

Summary: This study identified four subtypes of SCLC using RNA sequencing and immunohistochemistry, with the SCLC-Y subtype associated with an inflamed phenotype and favorable prognosis. Upregulation of interferon-gamma response genes was observed in long-term survivors, with higher expression in patients of the SCLC-Y subtype.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Hossein Borghaei et al.

Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

J. W. Goldman et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Edward B. Garon et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

L Paz-Ares et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

添加到收藏夹

Review Oncology

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

Charles M. Rudin et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

M. Catherine Pietanza et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.